Full Press Release Details
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences:
Guggenheim Emerging Outlook: Biotech Summit 2026Date:Thursday, February 12th, 2026Presentation Time:10:30AM ET
TD Cowen 46thAnnual Health Care ConferenceDate:Tuesday, March 3rd, 2026Presentation Time:1:10PM ET
UBS Biotech Summit MiamiDate:Monday March 9th, 2026
Jefferies Biotech on the Beach SummitDate:March 10th, 2026
Leerink Global Healthcare ConferenceDate: March 11th, 2026Presentation Time:1:00PM ET
Barclays 28thAnnual Global Healthcare ConferenceDate:March 12th, 2026Presentation Time:10:30AM ET
A webcast and replay of Oruka’s presentations will be available on the Oruka investor events website athttps://ir.orukatx.com/news-events/events-presentations.
About Oruka TherapeuticsOruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visitwww.orukatx.comand follow Oruka on LinkedIn.